BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 12794814)

  • 21. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeted ITP strategies: do they elucidate the biology of ITP and related disorders?
    Bennett CM; de Jong JL; Neufeld EJ
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):706-9. PubMed ID: 16933263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cell-ablative therapy for the treatment of autoimmune diseases.
    Patel DD
    Arthritis Rheum; 2002 Aug; 46(8):1984-5. PubMed ID: 12209499
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
    Lee JW; Kim HA; Sung JM; Suh CH
    Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus.
    ten Cate R; Smiers FJ; Bredius RG; Lankester AC; van Suijlekom-Smit LW; Huizinga TW; Egeler RM
    Rheumatology (Oxford); 2004 Feb; 43(2):244. PubMed ID: 14739467
    [No Abstract]   [Full Text] [Related]  

  • 28. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
    Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
    Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?
    Introna M; Golay J; Barbui T
    Haematologica; 2003 May; 88(5):482-4. PubMed ID: 12745265
    [No Abstract]   [Full Text] [Related]  

  • 30. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug insight: rituximab in renal disease and transplantation.
    Salama AD; Pusey CD
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab in autoimmune pancytopenia: a case report and review of literature.
    Reale LD; Besa EC
    Ann Hematol; 2007 Dec; 86(12):913-6. PubMed ID: 17541587
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab in the treatment of autoimmune haematological disorders.
    Garvey B
    Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prospects of the use of cyclosporin A in rheumatic diseases].
    Nasonov EL; Shtutman VZ; Nasonova VA
    Klin Med (Mosk); 1994; 72(5):12-9. PubMed ID: 7853807
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
    Taylor RP; Lindorfer MA
    Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.